Showing results (1-10 of 175) with videos related to
Sort By:
Pageof 18
Expert Opinion on Investigational Drugs|June 20, 2020
Novel agents for the treatment of polycythemia vera: an insight into preclinical research and early phase clinical trialsLeslie Padrnos, Ruben MesaExpert Review of Anticancer Therapy|September 7, 2016
The development, safety and efficacy of pacritinib for the treatment of myelofibrosisTania Jain, Ruben MesaExpert Opinion on Investigational Drugs|September 27, 2013
Emerging therapies for the treatment of chronic Philadelphia chromosome-negative myeloproliferative neoplasm-associated myelofibrosisKrisstina Gowin, Ruben MesaHematology. American Society of Hematology. Education Program|December 6, 2015
Evidence for Janus kinase (JAK) inhibitors for the prevention of major morbid events in patients with myeloproliferative neoplasms (MPNs)Naveen Pemmaraju, Ruben MesaFuture Oncology (London, England)|May 23, 2022
Momelotinib for the treatment of myelofibrosis with anemiaDouglas Tremblay, Ruben MesaCurrent Treatment Options in Oncology|January 14, 2023
New Treatments for MyelofibrosisDouglas Tremblay, Ruben MesaTherapeutic Advances in Hematology|June 2, 2020
The role of fedratinib for the treatment of patients with primary or secondary myelofibrosisJeanne Palmer, Ruben MesaClinical Lymphoma, Myeloma & Leukemia|June 25, 2023
Cross-Study Comparisons of JAK2 Inhibitors in Myelofibrosis: Risks and RecommendationsJohn Mascarenhas, Ruben MesaInternational Journal of Hematology|February 19, 2022
Novel treatments for myelofibrosis: beyond JAK inhibitorsDouglas Tremblay, Ruben MesaPageof 18